Innate Pharma presents long-term follow-up data from TELLOMAK trial

Innate Pharma (IPHA) announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sezary syndrome and mycosis fungoides, two rare and aggressive forms of cutaneous T-cell lymphoma. The results will be presented at the American Society of Clinical Oncology annual meeting, in Chicago, Illinois. As of October 17, 2024, data cut-off, lacutamab demonstrated compelling and sustained clinical activity in heavily pretreated patients, with a global ORR of 42.9% for SS and 19.6% for MF. With longer follow-up, we observed improved median duration of response of 25.6 months in SS and 13.8 months in MF, highlighting the durability of responses in these challenging indications. In addition, lacutamab was very well tolerated supporting the strong rationale for further investigations in combination beyond CTCL, especially in combination with other anti-lymphoma agents in peripheral T-cell lymphomas.